RxDoctor Payments Data

Kevin Fullin, MD

Cardiovascular Disease · Kenosha, WINPI 1346224532

Payments from drug & device makers

$3,260in general payments, 2019–2025

Across 92 payments — averaging $35.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$849
  • Abiomed$513
  • E.r. Squibb & Sons, L.L.C.$307
  • Boston Scientific$242
  • Actelion Pharmaceuticals US, Inc.$198
  • Novartis$164
  • plus $987 from 15 others

What the payments were for

  • Travel & lodging$80525%
  • Food & beverage$2,35672%
  • Education$993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,260 in reported general payments places this provider in the 65th percentile of 322 cardiovascular disease providers in Wisconsin.

See all cardiovascular disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$70,395
Medicare patients
794
Services billed
1,824

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban235$291,147
JardianceEmpagliflozin189$223,537
XareltoRivaroxaban88$102,707
EntrestoSacubitril/Valsartan33$50,446
FarxigaDapagliflozin Propanediol23$38,331
Repatha SureclickEvolocumab30$33,511
BrilintaTicagrelor39$31,317
ClopidogrelClopidogrel Bisulfate400$4,774
Metoprolol Succinate264$3,840
Digoxin32$3,825
Carvedilol315$3,189
Amiodarone Hcl49$2,477
Atorvastatin Calcium278$2,369
Nifedipine ErNifedipine71$2,326
Losartan Potassium187$1,942

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$128$291,147235 claims
Boehringer IngelheimJardiance$20$223,537189 claims
Johnson & JohnsonXarelto$60$102,70788 claims
AstraZenecaFarxiga, Brilinta$100$69,64862 claims
NovartisEntresto$164$50,44633 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 322 cardiovascular disease providers in Wisconsin.

Other cardiovascular disease in Kenosha

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →